ATA3219: Off-the-Shelf Allogeneic CD19 Program for Hematological and Autoimmune B-Cell Malignancies

  • ATA3219 CAR T
    • ATA3219 consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a second generation CD19 CAR construct
    • Currently under investigation in CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin’s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis)
    • ATA3219 manufacturing is based on clonally expanded EBV T cells, inherently having lower potential for alloreactivity
    • 1XX signaling domain optimizes expansion and mitigates T-cell exhaustion
    • ATA3219 CAR T cells have been designed for T-cell memory, expansion, and anti-tumor efficacy1
    • In vitro data reflect the CD19 antigen-specific functional activity of ATA3219 and CAR-mediated activity against B cells from SLE patients. ATA3219 led to CD19-specific B-cell depletion compared to controls2
    • Academic program generated proof-of-principle for an earlier-generation allogeneic CD19 targeted CAR EBV T-cell construct in relapsed/refractory B-cell malignancies after stem cell transplant.3
  1. Pham, C, et al. Abstract presented at Transplantation & Cellular Therapy (TCT) Meetings; 2023
  2. Atara internal unpublished data
  3. Curran KJ, et al. ASH 2023


ATA3219 is an allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, currently in clinical development, leveraging the EBV T-cell platform and features a next-generation 1XX co-stimulatory domain, memory phenotype, and unedited T-cell receptor.


  • Non-Hodgkin’s Lymphoma (NHL)
    Phase 1


  • Lupus Nephritis (LN)
    Systemic Lupus Erythematosus (SLE) without lymphodepletion
    Phase 1

Next-Generation CAR T Technology

Our CAR T pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaboration with Memorial Sloan Kettering Cancer Center.